نتائج البحث - "Vidarabine/therapeutic use"

1

Academic Journal

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

المؤلفون: Russell, Nigel H., Wilhelm-Benartzi, Charlotte, Othman, Jad, Dillon, Richard, Knapper, Steven, Batten, Leona M., Canham, Joanna, Hinson, Emily L., Betteridge, Sophie, Overgaard, Ulrik Malthe, Gilkes, Amanda, Potter, Nicola, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Freeman, Sylvie D., Dennis, Mike

المصدر: Russell , N H , Wilhelm-Benartzi , C , Othman , J , Dillon , R , Knapper , S , Batten , L M , Canham , J , Hinson , E L , Betteridge , S , Overgaard , U M , Gilkes , A , Potter , N , Mehta , P , Kottaridis , P , Cavenagh , J , Hemmaway , C , Arnold , C , Freeman , S D , Dennis , M & UK NCRI AML Working Group 2024 , ' Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin ....

مصطلحات موضوعية: Adult, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Core Binding Factors, Cytarabine/therapeutic use, Gemtuzumab/therapeutic use, Granulocyte Colony-Stimulating Factor/therapeutic use, Humans, Idarubicin, Leukemia, Myeloid, Acute/drug therapy, Mutation, Neoplasm Recurrence, Local/drug therapy, Nuclear Proteins/genetics, Progression-Free Survival, Recurrence, Vidarabine/therapeutic use, fms-Like Tyrosine Kinase 3

الاتاحة: https://pure.au.dk/portal/en/publications/706f709d-396d-48d1-8214-6c91f7effa6f
https://doi.org/10.1200/JCO.23.00943
http://www.scopus.com/inward/record.url?scp=85188441493&partnerID=8YFLogxK

View record in BASE

2

Academic Journal

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

المؤلفون: Mühleck, Regina, Scholl, Sebastian, Hilgendorf, Inken, Schrenk, Karin, Hammersen, Jakob, Frietsch, Jochen J., Fleischmann, Maximilian, Sayer, Herbert G., Glaser, Anita, Hochhaus, Andreas, Schnetzke, Ulf

المصدر: http://lobid.org/resources/99370674181806441#!, 148(9):2539-2548.

Relation: https://repository.publisso.de/resource/frl:6446900; https://doi.org/10.1007/s00432-021-03821-1; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349069/

الاتاحة: https://repository.publisso.de/resource/frl:6446900
https://doi.org/10.1007/s00432-021-03821-1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349069/

View record in BASE

3

Academic Journal

Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

المصدر: ISSN: 0268-3369 ; Bone marrow transplantation, vol. 56, no. 7 (2021) p. 1593-1602.

مصطلحات موضوعية: info:eu-repo/classification/ddc/616, Busulfan, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Neoplasms, Primary Myelofibrosis, Retrospective Studies, Thiotepa, Transplantation Conditioning, Vidarabine / analogs & derivatives, Vidarabine / therapeutic use

Relation: info:eu-repo/semantics/altIdentifier/pmid/33526919; https://archive-ouverte.unige.ch/unige:160591; unige:160591

الاتاحة: https://archive-ouverte.unige.ch/unige:160591

View record in BASE

4

Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

المساهمون: University of Naples Federico II = Università degli studi di Napoli Federico II, European Society for Blood and Marrow Transplantation (EBMT), Ospedale Policlinico San Martino [Genoa], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Università degli Studi di Roma Tor Vergata [Roma], Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Università degli Studi di Udine - University of Udine [Italie], Hôpitaux Universitaires de Genève (HUG), Azienda Ospedaliera Universitaria Senese, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), University Medical Centre Ljubljana [Ljubljana, Slovenia] (UMCL), University of Ljubljana, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Leiden University Medical Center (LUMC), Universiteit Leiden, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Trinity College Dublin, NHS Foundation Trust [London], The Royal Marsden, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

المصدر: Bone marrow transplantation, Vol. 56, No 7 (2021) pp. 1593-1602
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, 56 (7), pp.1593-1602. ⟨10.1038/s41409-021-01222-z⟩
BONE MARROW TRANSPLANTATION
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Bone Marrow Transplantation, 56(7), 1593-1602. SPRINGERNATURE

مصطلحات موضوعية: medicine.medical_specialty, Transplantation Conditioning, Platelet Engraftment, [SDV]Life Sciences [q-bio], Vidarabine / analogs & derivatives, Graft vs Host Disease, ThioTEPA, Gastroenterology, Conditioning regimen, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Neoplasms, medicine, Humans, In patient, Vidarabine / therapeutic use, Myelofibrosis, Busulfan, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, ddc:616, Transplantation, Hematopoietic cell, business.industry, Hematopoietic Stem Cell Transplantation, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Hematology, Middle Aged, Settore MED/15, medicine.disease, surgical procedures, operative, Primary Myelofibrosis, 030220 oncology & carcinogenesis, Stem cell, business, Thiotepa, Vidarabine, 030215 immunology, medicine.drug